Notably, a MR study reported inhibiting the IL6 signaling pathway via IL6R blockade might increase the risk of NAFLD, suggesting IL6R should play a protective role in NAFLD [54]. Here, IL6R is linked to metabolic dysfunction-associated steatotic liver disease.